GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-07-22	NT$23.45	-0.85%	98,706
26-07-21	NT$23.65	+1.28%	148,890
26-07-20	NT$23.35	-0.43%	170,007
26-07-17	NT$23.45	-2.09%	176,698
26-07-16	NT$23.95	-1.84%	169,596

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Taipei Exchange Other stock markets 2026-07-22			5-day change	1st Jan Change
23.45 ^TWD	-0.85%		-3.89%	-8.93%

Jun. 10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
May. 14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Market Cap	2.64B 81.35M 71.28M 66.17M 60.81M 115M 7.85B 116M 788M 309M 3.84B 305M 299M 13.27B	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	2.42B 74.58M 65.35M 60.66M 55.75M 105M 7.2B 107M 723M 283M 3.52B 280M 274M 12.16B	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	79.89%	Yield 2024 *	-	Yield 2025	-

Jun. 10	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
May. 14	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 14	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
Mar. 23	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
Mar. 13	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Dec. 08	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
Nov. 24	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
Nov. 14	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-10-29	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
25-10-29	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
25-08-13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-06-12	GlycoNex, Inc. Announces Publication of Preclinical Study on Gnx1021, A Novel Glycan-Targeted Adc for Gastric Cancer	CI
25-05-27	GlycoNex, Inc. Announces Publication of Research Involving Pro-Antibody, GNX201, in the International Journal of Biological Macromolecules	CI

1 day	-0.85%
1 week	-3.89%
Current month	-8.40%
1 month	-8.04%
3 months	-1.47%
6 months	-19.14%
Current year	-8.93%

GlycoNex Incorporation Stock

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news : GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Course Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

1 week	23	24.2
1 month	23	26.7
Current year	22.1	30
1 year	20.55	30
3 years	15.6	32.9
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	2018-12-31
Dih Fen Wu DFI	Director of Finance/CFO	-	2009-12-31
Yao Hua Lue IRC	Investor Relations Contact	-	2012-11-11

Director	Title	Age	Since
Tong Hsuan Chang CHM	Chairman	-	2001-01-31
Kao Chung Tsai BRD	Director/Board Member	64	-
Ling-Chun Tsai BRD	Director/Board Member	-	2012-05-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	-0.85%	-3.89%	-1.68%	-22.22%	81.35M
LONZA GROUP AG	+1.04%	-5.25%	-4.49%	+12.26%	46.06B
REVOLUTION MEDICINES, INC.	+3.77%	+3.56%	+394.44%	+615.36%	38.91B
BEONE MEDICINES AG	+0.13%	+1.54%	+9.32%	+65.08%	35.57B
IQVIA HOLDINGS INC.	+5.96%	+0.79%	+9.22%	-7.02%	33.13B
CELLTRION, INC.	-0.87%	-3.19%	-1.27%	+29.16%	26.42B
ASCENDIS PHARMA A/S	+0.41%	-2.63%	-	-	16.61B
MEDPACE HOLDINGS, INC.	+18.08%	+20.29%	+47.93%	+162.04%	15.08B
EUROFINS SCIENTIFIC SE	-4.82%	-3.34%	+6.03%	+9.77%	14.08B
ICON PUBLIC LIMITED COMPANY	+5.28%	+5.40%	+6.72%	-26.15%	12.81B
Average	+2.82%	-2.24%	+51.80%	+93.14%	23.87B
Weighted average by Cap.	+2.74%	-2.60%	+74.90%	+133.28%

	2024	2025
Net sales	14.7M 453K 397K 369K 339K 638K 43.74M 648K 4.39M 1.72M 21.4M 1.7M 1.66M 73.93M	37.86M 1.17M 1.02M 950K 873K 1.64M 113M 1.67M 11.31M 4.43M 55.12M 4.38M 4.29M 190M
Net income	-230M -7.08M -6.21M -5.76M -5.29M -9.98M -683M -10.12M -68.63M -26.86M -334M -26.59M -26.01M -1.16B	-235M -7.25M -6.35M -5.9M -5.42M -10.21M -700M -10.37M -70.28M -27.51M -342M -27.23M -26.64M -1.18B
Net Debt	-442M -13.63M -11.94M -11.09M -10.19M -19.2M -1.32B -19.48M -132M -51.7M -644M -51.17M -50.07M -2.22B	-220M -6.77M -5.94M -5.51M -5.06M -9.54M -654M -9.68M -65.64M -25.69M -320M -25.43M -24.88M -1.1B